CASI Pharmaceuticals, Inc. (CASI)
USD 2.1
(7.56%)
USD 2.1
(7.56%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.96 Million | -21.08 Million | -26.84 Million | -25.88 Million | -23.24 Million | -28.58 Million |
| Net Income | -26.93 Million | -40.25 Million | -35.84 Million | -47.51 Million | -45.36 Million | -27.47 Million |
| Depreciation & Amortization | 3.74 Million | 2.42 Million | 1.81 Million | 1.95 Million | 2.15 Million | 1.67 Million |
| Deferred income taxes | -20.45 Million | - | -5.2 Million | -3.93 Million | 1.23 Million | 325.45 Thousand |
| Stock-based compensation | 7.21 Million | 7.01 Million | 7.77 Million | 7.82 Million | 7.31 Million | 6.11 Million |
| Change in working capital | -7.81 Million | -6.65 Million | -3.21 Million | -3.31 Million | 4.45 Million | -9.78 Million |
| Other non-cash items | 24.28 Million | 16.38 Million | 7.83 Million | 19.1 Million | 6.96 Million | 553.57 Thousand |
| Investing Cash Flow | -9.67 Million | 31.15 Million | -20.69 Million | -20.71 Million | -28.05 Million | -21.77 Million |
| Investments in PPE | -2.24 Million | -5.61 Million | -15.5 Million | -19.32 Million | -14.02 Million | -21.77 Million |
| Acquisitions | - | 138 Thousand | 10 Thousand | - | 20 Million | -20.64 Million |
| Investment purchases | -51.75 Million | -7.42 Million | -12.4 Million | -83 Thousand | -14.03 Million | - |
| Sales/Maturities of investments | 43.32 Million | 37.62 Million | 172 Thousand | - | -13.03 Million | - |
| Other Investing Activities | 1 Million | 6.43 Million | 7.02 Million | -1.3 Million | -6.96 Million | 20.64 Million |
| Financing Cash Flow | -907 Thousand | -3.26 Million | 29.64 Million | 47.15 Million | 22.04 Million | 92.26 Million |
| Debt repayment | - | -4 Million | -1.54 Million | -1.24 Million | -1.5 Million | - |
| Dividends payments | -738 Thousand | - | - | - | - | - |
| Common Stock Repurchased | -278 Thousand | -3.26 Million | - | -251 Thousand | -367 Thousand | -117 Thousand |
| Common Stock Issuance | 109 Thousand | - | 32.5 Million | 46.15 Million | 182 Thousand | 87.99 Million |
| Other Financing Activities | -738 Thousand | 4 Million | -1.31 Million | 47.4 Million | 24.09 Million | 4.27 Million |
| Accounts receivables | 2.83 Million | -3.17 Million | -5.15 Million | -3.35 Million | -1.29 Million | - |
| Accounts payables | 1.14 Million | 1.06 Million | 1.49 Million | -1.54 Million | 4 Million | -1.09 Million |
| Inventory | -9.73 Million | -4.23 Million | -551 Thousand | 3.18 Million | -4.41 Million | -283 Thousand |
| Other working capital | -2.06 Million | -315 Thousand | 1 Million | -1.61 Million | 6.15 Million | -8.68 Million |
| Cash at beginning of period | 47.11 Million | 38.7 Million | 57.06 Million | 53.62 Million | 84.2 Million | 43.48 Million |
| Cash at end of period | 17.08 Million | 47.11 Million | 38.7 Million | 57.06 Million | 53.62 Million | 84.2 Million |
| Capital Expenditure | -2.24 Million | -5.61 Million | -15.5 Million | -19.32 Million | -14.02 Million | -21.77 Million |
| Effect of forex changes on cash | 518 Thousand | 1.6 Million | -469 Thousand | 2.89 Million | -1.32 Million | -1.19 Million |
| Net cash flow / Change in cash | -30.02 Million | 8.4 Million | -18.36 Million | 3.44 Million | -30.58 Million | 40.71 Million |
| Free Cash Flow | -22.2 Million | -26.7 Million | -42.34 Million | -45.21 Million | -37.26 Million | -50.35 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.52 Million | -26.93 Million | -6.05 Million | -4.63 Million | -10.23 Million | -6 Million |
| Depreciation & Amortization | - | 3.74 Million | - | - | - | - |
| Deferred income taxes | - | -20.45 Million | - | - | - | - |
| Stock-based compensation | - | 7.21 Million | 7.21 Million | - | - | - |
| Change in working capital | - | -7.81 Million | - | - | - | - |
| Other non-cash items | 9.52 Million | 24.28 Million | -1.16 Million | 4.63 Million | 10.23 Million | 6 Million |
| Investing Cash Flow | - | -9.67 Million | - | - | - | - |
| Investments in PPE | - | -2.24 Million | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -51.75 Million | - | - | - | - |
| Sales/Maturities of investments | - | 43.32 Million | - | - | - | - |
| Other Investing Activities | - | 1 Million | - | - | - | - |
| Financing Cash Flow | - | -907 Thousand | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | -738 Thousand | - | - | - | - |
| Common Stock Repurchased | - | -278 Thousand | - | - | - | - |
| Common Stock Issuance | - | 109 Thousand | - | - | - | - |
| Other Financing Activities | - | -738 Thousand | - | - | - | - |
| Accounts receivables | - | 2.83 Million | - | - | - | - |
| Accounts payables | - | 1.14 Million | - | - | - | - |
| Inventory | - | -9.73 Million | - | - | - | - |
| Other working capital | - | -2.06 Million | - | - | - | - |
| Cash at beginning of period | - | 47.11 Million | - | - | - | 47.11 Million |
| Cash at end of period | - | 17.08 Million | - | - | - | 47.11 Million |
| Capital Expenditure | - | -2.24 Million | - | - | - | - |
| Effect of forex changes on cash | - | 518 Thousand | - | - | - | - |
| Net cash flow / Change in cash | - | -30.02 Million | - | - | - | - |
| Free Cash Flow | - | -22.2 Million | - | - | - | - |
2389
300978
0URY
4120
CRRVF
6916